According to FutureWise analysis the market for Anaplastic Large Cell Lymphoma (ALCL) Therapeutics in 2023 is US$ 11.05 billion, and is expected to reach US$ 16.6 billion by 2031 at a CAGR of 5.20%.
Anaplastic large cell lymphoma is a rare type of Non Hodgkin lymphoma and a common subtype of T-cell lymphoma. ALCL can occur at any age but is more common in children and young adults. It affects more men than women. Rarely anaplastic large cell lymphoma can develop in the scar tissue around a breast implant. This is called breast implant-associated ALCL (BIA-ALCL). Recent analysis suggests the risk is higher in women with textured implants than those with smooth surfaces. ALCL is grouped based on if there is a specific gene transformation in the lymphoma cells. Change in the gene causes the cells to produce a protein called anaplastic lymphoma kinase, or ALK1. The lymphoma cells with the gene changes have a marker on the surface called the CD30 antigen, also known as the Ki-1 antigens. If the ALK1 gene change is present, it is called as ALK-positive ALCL. If this gene change is not present, it is as called ALK-negative ALCL.
ALCL is treated with standard chemotherapy. Other therapies include stem cell transplants, radiotherapy, and steroid therapy. People with ALK-positive ALCL usually respond well to chemotherapy. Primary ALCL may spontaneously remission (the disease disappears without treatment). Yet this is inevitably followed by a relapse. If no spontaneous remission appears, or if the lymphoma relapses, the most common type of treatment for this type of ALCL includes radiation therapy or surgery to remove the affected skin area.
FutureWise Market Research has published a report that provides an insightful analysis anaplastic large cell lymphoma (ALCL) therapeutics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.
According to the analysis conducted by FutureWise research analysts, anaplastic large cell lymphoma (ALCL) therapeutics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.